Late-Stage Antibiotic Firm Trius Prices $45M Offering

A little more than a month after reporting positive data from the first of two pivotal trials testing antibiotic tedizolid phosphate in Gram-positive skin infections, Trius Therapeutics Inc. is shoring up its cash balance with a $45.2 million public offering.